Ahead of the announcement of our cell therapy pipeline and lead candidate, 911±¬ÁÏÍø CEO Mark Kotter spoke with Endpoints News.
The piece covers our lead cell therapy candidate for acute liver failure - bbHEP01 - and the wider cell therapy pipeline that was announced on 8 November. They also cover ´Ç±è³Ù¾±-´Ç³æâ„¢ and the overall cell programming approach that we are taking to produce human cells that are consistent at scale for therapies.